T Cell
Blockade of T-Cell Costimulatory Pathways
Biologic Therapies
‘Gratifying’ results show ‘incredible step forward’ for off-the-shelf T-cell therapies
The first published results of a phase 3 allogeneic T-cell therapy showed a better than 50% response rate in patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
Patients with multiple autoimmune diseases may improve from targeting shared pathways
Patients with multiple diseases that share immunologic pathways may benefit from therapies that target those shared pathways, but additional studies are needed in this area, according to a presenter at the 2023 AWIR annual conference.
VIDEO: New CAR T-cell therapies ‘waiting in the wings’ for patients with leukemia
In this video, Eunice Wang, MD, discussed an abstract relating to new chimeric antigen receptor T-cell therapies treating acute lymphocytic leukemia, presented at ASCO Annual Meeting.
CAR T-cell therapy, new drugs ushering in ‘lupus renaissance’
SCOTTSDALE, Ariz. — Several new drugs and promising therapies, including chimeric antigen receptor T-cell therapy, have ushered in a “lupus renaissance,” said a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.
CAR T-cell recipients receive more psychological support, fear cancer progression less
Patients who received chimeric antigen receptor T cells for relapsed or refractory diffuse large B-cell lymphoma feared disease progression less than those who received standard regimens, results of a cross-sectional study showed.
Neurodegenerative biomarker may predict CAR T-cell therapy-related neurotoxicity
A blood test may predict which patients are predisposed to developing treatment-related neurotoxicity after chimeric antigen receptor T-cell therapy infusion, according to researchers.
VIDEO: Advances in CAR T-cell manufacturing, real-world data highlighted at ASH
NEW ORLEANS — Making chimeric antigen receptor T cells quickly is going to become a reality, according to Nikhil C. Munshi, MD, who discusses presentations from the ASH Annual Meeting and Exposition in this video perspective.
VIDEO: CAR T-cell access lags for those with relapsed refractory multiple myeloma
NEW ORLEANS — In this video, Samer Al Hadidi, MD, MS, FACP, discusses an analysis of access to chimeric antigen receptor T-cell therapy presented at the ASH Annual Meeting and Exposition.